Consecuencias renales del uso de esteroides anabolizantes y práctica de culturismo

García, Enoc Merino; Utiel, Francisco José Borrego; Arcos, M.Ángeles Martínez; Hinojosa, Josefa Borrego; Barrio, Pilar Pérez del

doi:10.1016/j.nefro.2017.03.004

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On third admission, diagnosed with chronic kidney disease and coronary artery disease (2013)Advice given to discontinue AAS initially. Surgery at later presentation. [136]SpainCRSevere acute kidney failure with high blood pressure, anaemia and thrombocytopeniaMedical therapy [137]IranCRAcute renal failure; muscle injury and rhabdomyolysisMedical therapy [138]BrazilCSAcute kidney injury in both casesMedical therapy. [139]USACRRecurrent renal infarctionMedical therapy, AAS counselling [140]LebanonCRAcute pancreatitis, acute renal failure and hypercalcemia.Medical therapyCardiovascular ( n = 26) [141]JapanCRCardioembolic strokeMedical therapy, AAS use discontinued [142]SwedenCRIntraparenchymal haemorrhage in right parietal lobe; right cortical venous thrombosisAnticoagulation therapy [143]UKCRAcute myocardial infarctionSurgery [144]EgyptCRSevere toxic cardiomyopathy.Medical therapy [145]CanadaCRCardiomyopathyIncubation, medical therapy, resuscitation, dialysis and device implantation, addiction counselling referral [146]ArgentinaCRPosterior territory ischemic stroke.Intubation and ventilation; rehabilitation [147]SwedenCRSevere hypertensionAggressive treatment with intravenous drugs; AAS cessation [148]TurkeyCRAcute coronary syndromeMedical therapy [149]SwedenCSi) Occlusion of all major arteries of the leg.ii) Arterial thrombosis:i) Surgeryii) Thrombolysis attempted with no improvement. Surgery performed. [150]CanadaCRStroke.…”

Section: Resultsmentioning

confidence: 99%

Treatments for people who use anabolic androgenic steroids: a scoping review

et al. 2019

View full text Add to dashboard Cite

Background: A growing body of evidence suggests that anabolic androgenic steroids (AAS) are used globally by a diverse population with varying motivations. Evidence has increased greatly in recent years to support understanding of this form of substance use and the associated health harms, but there remains little evidence regarding interventions to support cessation and treat the consequences of use. In this scoping review, we identify and describe what is known about interventions that aim to support and achieve cessation of AAS, and treat and prevent associated health problems.Methods: A comprehensive search strategy was developed in four bibliographic databases, supported by an iterative citation searching process to identify eligible studies. Studies of any psychological or medical treatment interventions delivered in response to non-prescribed use of AAS or an associated harm in any setting were eligible. Results: In total, 109 eligible studies were identified, which included case reports representing a diverse range of disciplines and sources. Studies predominantly focussed on treatments for harms associated with AAS use, with scant evidence on interventions to support cessation of AAS use or responding to dependence. The types of conditions requiring treatment included psychiatric, neuroendocrine, hepatic, kidney, cardiovascular, musculoskeletal and infectious. There was limited evidence of engagement with users or delivery of psychosocial interventions as part of treatment for any condition, and of harm reduction interventions initiated alongside, or following, treatment. Findings were limited throughout by the case report study designs and limited information was provided.Conclusion: This scoping review indicates that while a range of case reports describe treatments provided to AAS users, there is scarce evidence on treating dependence, managing withdrawal, or initiating behaviour change in users in any settings. Evidence is urgently required to support the development of effective services for users and of evidence-based guidance and interventions to respond to users in a range of healthcare settings. More consistent reporting in articles of whether engagement or assessment relating to AAS was initiated, and publication within broader health-or drug-related journals, will support development of the evidence base.

show abstract

Section: Resultsmentioning

confidence: 99%

Treatments for people who use anabolic androgenic steroids: a scoping review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In a recent case report, Garcia et al. described acute kidney failure in a bodybuilder who had taken intramuscular anabolic-androgenic steroids (testosterone and stanozolol) ( Merino García et al., 2018 ). Another study reported that FSGS had been frequently detected in AAS users, suggesting two mechanisms of action: direct glomerular toxicity and glomerular hyperfiltration related to the increased body mass of abusers ( Herlitz et al., 2010 ).…”

Section: Discussionmentioning

confidence: 99%

miRNAs as Novel Biomarkers of Chronic Kidney Injury in Anabolic-Androgenic Steroid Users: An Experimental Study

et al. 2020

View full text Add to dashboard Cite

miRNAs are a family of 20-22 non-coding nucleotides that control gene expression by inhibiting the translation of their target messenger RNAs (mRNAs). Two models have been proposed to elucidate the mechanism of action: they act either hindering mRNA translation or enhancing mRNA degradation. Anabolic-Androgenic Steroids (AASs) represent a class of drugs used to treat several diseases. In the last few years, AASs have frequently been used for aesthetic purposes, indeed, they form part of the larger group called image-and performance-enhancing drugs (IPEDs). Long-term AAS use can lead to serious health consequences. In this regard, the present study aimed to analyze the role of several microRNAs (miRNAs) in renal damage after AAS use, to better understand the underlying mechanisms. For this purpose, two miRNAs (miR-21 and miR-205) were tested in two groups: AAS group (seven males, mean age 33.28 ± 4.68 years; mean body mass index (BMI) 27.04 ± 1.07), and chronic kidney disease (CKD) group (seven males, mean age 66.2 ± 5.4 years; mean BMI 24.75 ± 1.35). Finally, the same miRNAs were tested in the "Control" group (seven males, mean age 44.85 ± 5.75 years; mean BMI 26.5 ± 1.88). Kolmogorov-Smirnov Test was used to determine the normality of data distribution. All variables were normally distributed. Student's t-test was used for comparisons between two groups. Analyzing the results of the present study, the two tested miRNAs (miR-21 and miR-205) were significantly higher in the CKD group compared to the AAS group, with mir-21 being much more expressed than miR-205. This study represents a pilot study to define if these expression patterns could be studied in other biological samples (plasma, urine) in subjects with different kidney injury linked to chronic kidney diseases and AAS use, to identify reliable biomarkers that could be applied in clinical and forensic diagnostics, as well as a target for toxicological investigations or therapeutic treatments.

show abstract